Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer
NEJM Evidence · 2026
DOI: 10.1056/evidoa2500120 ↗Kurz gefasst
Fachartikel in der Zeitschrift NEJM Evidence, 2026. Verfasst von Maliha Nusrat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Thymine, Pyrrolidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Taiho Oncology, Inc., Princeton, NJ, USA.
- ConcertAI, LLC, Cambridge, MA, USA.
- Fox Chase Cancer Center, Philadelphia, PA, USA.
Zitieren
APA
Nusrat, M., Zhao, R., Khan, N., Wang, Y., Penney, K. L., Cann, C. G., & Salimi, T. (2026). Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer. NEJM Evidence. https://doi.org/10.1056/evidoa2500120
Vancouver
Nusrat M, Zhao R, Khan N, Wang Y, Penney KL, Cann CG, et al. Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer. NEJM Evidence. 2026. doi:10.1056/evidoa2500120
BibTeX
@article{Nusrat2026,
author = {Nusrat, Maliha and Zhao, Ruizhi and Khan, Nadeem and Wang, Yuexi and Penney, Kathryn L and Cann, Christopher G and Salimi, Tehseen},
title = {Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer},
journal = {NEJM Evidence},
year = {2026},
doi = {10.1056/evidoa2500120}
}
EUVIMED